| Product Name | Mirdametinib (PD0325901) |
|---|---|
| CAS | 391210-10-9 |
| Formula | C16H14F3IN2O4 |
| MW | 482.19 |
| Appearance | White powder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity |
|---|---|---|---|---|
| 10 mg | In-stock | ¥426.00 | Visible after login | |
| 50 mg | In-stock | ¥1266.00 | Visible after login | |
| 100 mg | In-stock | ¥1986.00 | Visible after login |
| Product Name | Mirdametinib (PD0325901) |
|---|---|
| CAS | 391210-10-9 |
| Formula | C16H14F3IN2O4 |
| MW | 482.19 |
| Appearance | White powder |
| Storage condition | Dry, dark and at 0 - 4 ℃ for short term (days to weeks) or -20 ℃ for long term (months to years). |
Mirdametinib, also known as PD-0325901, is a potent bioavailable and selective MEK inhibitor, which targets mitogen-activated protein kinase kinase (MAPK/ERK kinase or MEK) with potential antineoplastic activity. MEK inhibitor PD325901, a derivative of MEK inhibitor CI-1040, selectively binds to and inhibits MEK, which may result in the inhibition of the phosphorylation and activation of MAPK/ERK and the inhibition of tumor cell proliferation. The dual specific threonine/tyrosine kinase MEK is a key component of the RAS/RAF/MEK/ERK signaling pathway that is frequently activated in human tumors.